APOE and Alzheimer disease: This could further clarify the mechanisms by which systemic inflammation in COVID-19 accelerates AD pathology, and how certain populations of cells, such as APOE ε4/ε4 carriers, may exhibit differential responses, potentially due to altered receptor expression or impaired immune responses.